PMC8529157_01
PMC8529157_02
PMC8529157_03
PMC8529157_04
Allele frequency of HLA types in HSCT patients with sarcoidosis compared to German and European normal population cohorts. Box plots of HLA allele frequencies in Europe shown where available. The calculation of allele frequency in our cohort and published case report cohorts were obtained via direct counting (number of observations for a given allele divided by the number of haplotypes [2 n, where n = sample size]). UMG, University Medical Center Gottingen.
fimmu-12-746996-g002.jpg
PMC8529157_04_fimmu-12-746996-g002.jpg
f2
The allele frequencies for the respective genotypes in this cohort were, in turn, higher than the allele frequency reported in a German and European reference population (Figure 2).
(A) Cumulative incidence of sarcoidosis over time in the whole cohort. (B) Cumulative incidence of sarcoidosis in allogenous HSCT versus autologous HSCT. The median time to onset of sarcoidosis post HSCT overall was 17 months (range 3 to 120 months), with patients developing sarcoidosis after allo HSCT at a median time of 20 months (range 3 to 30 months) and 7 months (range 3 to 120 months) after auto HSCT. No statistically significant difference between the groups could be detected (p = 0.5422).
fimmu-12-746996-g003.jpg
PMC8529157_04_fimmu-12-746996-g003.jpg
f3
The median time to onset of sarcoidosis post HSCT overall was 17 months (range 3 to 120 months), with patients developing sarcoidosis after allo HSCT at a median time of 20 months (range 3 to 30 months) and 7 months (range 3 to 120 months) after auto HSCT (p = 0.5422) (Figure 3A). In patients over 50 years of age, the median time to sarcoidosis after HSCT was 12 months, while it was 21 months in patients younger than 50 years (p = 0.1438) (Figure 3B).
(A-E) Cumulative incidence of sarcoidosis over time. (A) Comparison of MRD versus MUD donor status. (B) Male versus female patients. (C) Leukemia versus lymphoma/MDS/MF. (D) Comparison of patients aged older than 50 years versus younger than 50 years. (E) Comparison of hematological versus solid malignancies. No statistically significant differences could be detected. MDS, myelodysplastic syndrome; MF, myelofibrosis; MRD, matched related donor; MUD, matched unrelated donor.
fimmu-12-746996-g004.jpg
PMC8529157_04_fimmu-12-746996-g004.jpg
f4
Furthermore, we analyzed the cumulative incidence of sarcoidosis depending on gender, donor status (MRD/MUD), solid vs. hematological neoplasia, and lymphoma vs. leukemia/MDS/MF (Figures 4A-E).